Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib

A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuat...

Full description

Bibliographic Details
Main Authors: Nagano, Tatsuya, Kotani, Yoshikazu, Kobayashi, Kazuyuki, Katsurada, Masahiro, Hatakeyama, Yukihisa, Hori, Suya, Tamura, Daisuke, Kasai, Daisuke, Funada, Yasuhiro, Nishimura, Yoshihiro
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420486/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420486/

Similar Items